To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

NCT07684820 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: EXPD-101/FXS7553 Dose 1
DRUG: EXPD-101/FXS7553 Dose 2
DRUG: Placebo

Sponsor

Expedition Therapeutics, Inc